Abbott announced new four-year data showing the long-term and sustained relief that its proprietary BurstDR™ spinal cord stimulation (SCS) technology provides people with chronic pain, particularly ...

Therapeutic breakthroughs in neuromodulation merge wearable technologies, deep brain implants, and tailored stimulations while engineers refine cooling techniques, improve battery resilience, and ...

The Inceptiv data give Medtronic more evidence as it tries to increase sales of a product that drove double-digit growth at ...

Q4 2024 Earnings Call Transcript January 22, 2025 Abbott Laboratories reports earnings inline with expectations. Reported EPS is $1.34 EPS, expectations were $1.34. Operator: Good morning and thank ...

Welcome to Abbott's fourth quarter 2024 earnings conference call. [Operator instructions] This call is being recorded by Abbott. With the exception of any participants' questions asked during the ...

Welcome to Abbott’s Fourth Quarter 2024 Earnings ... demand in international markets for our Eterna rechargeable spinal cord stimulation device. So in summary, we delivered another quarter ...

A long-term study of patients treated with one of Medtronic’s spinal cord stimulation devices found that 80% continued to use their devices after five years to manage their pain. Abbott’s Proclaim XR ...

Bolt Acquisition Deal Drives BSX Stock Close to 52-Week High Boston Scientific stock is currently trading close to its 52-week high. In the past four trading sessions, the stock has consistently ...

Billed as the world’s most advanced wearable robotic exoskeleton, XoMotion from Vancouver, Canada’s Human In Motion Robotics Inc. is designed to assist patients with mobility impairments from spinal ...